HERVolution Publishes Foundational Data Demonstrating Rationally Engineered HERV-K Antigens Can Break Immune Tolerance and Train Immune Cells to Target Cancer Cells

Summary

Peer-reviewed study describes the rationally engineered envelope modification underpinning HERVolution's lead program, IPT-001, and detects HERV-K expression across the majority of 43 cancer types in 1,353 patients…